Cocrystal Pharma, Inc. (COCP) News
Follow Cocrystal Pharma, Inc. (COCP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cocrystal Pharma doses last subject in Phase 1b norovirus study
Cocrystal Pharma said the last subject was dosed in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected late 2026 or early 2027.
EARNINGS | Sep 09, 2026, 12:03 PM UTC
L
COCP doses last subject in Phase 1b CDI-988 norovirus challenge
Cocrystal Pharma said it dosed the last subject in its Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment.
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
Cocrystal Pharma appoints Carol Brosgart, MD to board
Cocrystal Pharma (COCP) appoints Carol Brosgart, MD to its Board of Directors, according to TradeXchange Newsdesk.
REGULATION | Aug 17, 2026, 03:17 PM UTC
M
Cocrystal Pharma Announces $5M Private Placement
Cocrystal Pharma raises $5 million in private placement
EQUITY | Aug 03, 2026, 11:00 AM UTC